KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Thermo Fisher Scientific (TMO) Short-Term Debt issuances (2016 - 2026)

Thermo Fisher Scientific filings provide 16 years of Short-Term Debt issuances readings, the most recent being $389.0 million for Q1 2026.

  • On a quarterly basis, Short-Term Debt issuances changed N/A to $389.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $389.0 million, a N/A change, with the full-year FY2025 number at $1.1 billion, changed N/A from a year prior.
  • Short-Term Debt issuances hit $389.0 million in Q1 2026 for Thermo Fisher Scientific, down from $593.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $1.0 billion in Q2 2023 to a low of $199.0 million in Q4 2022.
  • Median Short-Term Debt issuances over the past 3 years was $406.0 million (2022), compared with a mean of $505.0 million.
  • Biggest five-year swings in Short-Term Debt issuances: crashed 88.26% in 2022 and later soared 64.06% in 2023.
  • Thermo Fisher Scientific's Short-Term Debt issuances stood at $295.0 million in 2022, then skyrocketed by 101.02% to $593.0 million in 2023, then tumbled by 34.4% to $389.0 million in 2026.
  • The last three reported values for Short-Term Debt issuances were $389.0 million (Q1 2026), $593.0 million (Q3 2023), and $1.0 billion (Q2 2023) per Business Quant data.